204 related articles for article (PubMed ID: 24964963)
1. Podoplanin--a novel marker in oral carcinogenesis.
Swain N; Kumar SV; Routray S; Pathak J; Patel S
Tumour Biol; 2014 Sep; 35(9):8407-13. PubMed ID: 24964963
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical Expression of Podoplanin in Clinical Variants of Oral Leukoplakia and Its Correlation With Epithelial Dysplasia.
D'souza B; Nayak R; Kotrashetti VS
Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):132-139. PubMed ID: 27153448
[TBL] [Abstract][Full Text] [Related]
3. Dual role of podoplanin in oral cancer development.
Cîrligeriu L; Cimpean AM; Raica M; Doroş CI
In Vivo; 2014; 28(3):341-7. PubMed ID: 24815836
[TBL] [Abstract][Full Text] [Related]
4. Podoplanin and ABCG2: malignant transformation risk markers for oral lichen planus.
Shi P; Liu W; Zhou ZT; He QB; Jiang WW
Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):844-9. PubMed ID: 20200437
[TBL] [Abstract][Full Text] [Related]
5. Podoplanin emerges as a functionally relevant oral cancer biomarker and therapeutic target.
Retzbach EP; Sheehan SA; Nevel EM; Batra A; Phi T; Nguyen ATP; Kato Y; Baredes S; Fatahzadeh M; Shienbaum AJ; Goldberg GS
Oral Oncol; 2018 Mar; 78():126-136. PubMed ID: 29496040
[TBL] [Abstract][Full Text] [Related]
6. Podoplanin expressing cancer-associated fibroblasts in oral cancer.
Inoue H; Tsuchiya H; Miyazaki Y; Kikuchi K; Ide F; Sakashita H; Kusama K
Tumour Biol; 2014 Nov; 35(11):11345-52. PubMed ID: 25119595
[TBL] [Abstract][Full Text] [Related]
7. Podoplanin expression in oral leukoplakia: tumorigenic role.
de Vicente JC; Rodrigo JP; Rodriguez-Santamarta T; Lequerica-Fernández P; Allonca E; García-Pedrero JM
Oral Oncol; 2013 Jun; 49(6):598-603. PubMed ID: 23473850
[TBL] [Abstract][Full Text] [Related]
8. Expression of podoplanin in oral premalignant and malignant lesions and its potential as a biomarker.
Logeswari J; Malathi N; Thamizhchelvan H; Sangeetha N; Nirmala SV
Indian J Dent Res; 2014; 25(3):305-10. PubMed ID: 25098985
[TBL] [Abstract][Full Text] [Related]
9. Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy.
Kawaguchi H; El-Naggar AK; Papadimitrakopoulou V; Ren H; Fan YH; Feng L; Lee JJ; Kim E; Hong WK; Lippman SM; Mao L
J Clin Oncol; 2008 Jan; 26(3):354-60. PubMed ID: 18202409
[TBL] [Abstract][Full Text] [Related]
10. Podoplanin expression in oral leukoplakia─a prospective study.
Grochau KJ; Safi AF; Drebber U; Grandoch A; Zöller JE; Kreppel M
J Craniomaxillofac Surg; 2019 Mar; 47(3):505-509. PubMed ID: 30638740
[TBL] [Abstract][Full Text] [Related]
11. Role of podoplanin in potentially malignant disorders and oral squamous cell carcinoma and its correlation with lymphangiogenesis.
Parhar S; Kaur H; Vashist A; Verma S
Indian J Cancer; 2015; 52(4):617-22. PubMed ID: 26960495
[TBL] [Abstract][Full Text] [Related]
12. Podoplanin expression correlates with sentinel lymph node metastasis in early squamous cell carcinomas of the oral cavity and oropharynx.
Huber GF; Fritzsche FR; Züllig L; Storz M; Graf N; Haerle SK; Jochum W; Stoeckli SJ; Moch H
Int J Cancer; 2011 Sep; 129(6):1404-9. PubMed ID: 21105028
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of podoplanin expression in oral squamous cell carcinoma--a regression model auxiliary to UICC classification.
Seki S; Fujiwara M; Matsuura M; Fujita S; Ikeda H; Umeda M; Asahina I; Ikeda T
Pathol Oncol Res; 2014 Jul; 20(3):521-8. PubMed ID: 24281769
[TBL] [Abstract][Full Text] [Related]
14. Podoplanin expression in tumor-free resection margins of oral squamous cell carcinomas: an immunohistochemical and fractal analysis study.
Margaritescu C; Raica M; Pirici D; Simionescu C; Mogoanta L; Stinga AC; Stinga AS; Ribatti D
Histol Histopathol; 2010 Jun; 25(6):701-11. PubMed ID: 20376776
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of SOX2 and podoplanin expression in oral epithelial dysplasia and its correlation with malignant transformation.
Verma V; Chandrashekar C
J Investig Clin Dent; 2019 Nov; 10(4):e12450. PubMed ID: 31464104
[TBL] [Abstract][Full Text] [Related]
16. S100A7 overexpression is a predictive marker for high risk of malignant transformation in oral dysplasia.
Kaur J; Matta A; Kak I; Srivastava G; Assi J; Leong I; Witterick I; Colgan TJ; Macmillan C; Siu KW; Walfish PG; Ralhan R
Int J Cancer; 2014 Mar; 134(6):1379-88. PubMed ID: 24122701
[TBL] [Abstract][Full Text] [Related]
17. Ebp1 activates podoplanin expression and contributes to oral tumorigenesis.
Mei Y; Zhang P; Zuo H; Clark D; Xia R; Li J; Liu Z; Mao L
Oncogene; 2014 Jul; 33(29):3839-50. PubMed ID: 23975429
[TBL] [Abstract][Full Text] [Related]
18. [Molecular risk markers for malignant transformation of oral mucosal leukoplakia ].
Skorodumova LO; Muriaev AA; Volodina EV; Ivanov SIu; Gnuchev NV; Georgiev GP; Larin SS
Vopr Onkol; 2012; 58(3):327-32. PubMed ID: 22888646
[No Abstract] [Full Text] [Related]
19. The pattern of expression of the 5T4 oncofoetal antigen on normal, dysplastic and malignant oral mucosa.
Ali A; Langdon J; Stern P; Partridge M
Oral Oncol; 2001 Jan; 37(1):57-64. PubMed ID: 11120484
[TBL] [Abstract][Full Text] [Related]
20. Expression of podoplanin and prognosis in oropharyngeal cancer.
Preuss SF; Anagiotos A; Seuthe IM; Drebber U; Wedemeyer I; Kreppel M; Semrau R; Eslick GD; Klussmann JP; Huebbers CU
Eur Arch Otorhinolaryngol; 2015 Jul; 272(7):1749-54. PubMed ID: 24880471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
